These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28546419)

  • 1. Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface.
    Hudson RP; Dawson JE; Chong PA; Yang Z; Millen L; Thomas PJ; Brouillette CG; Forman-Kay JD
    Mol Pharmacol; 2017 Aug; 92(2):124-135. PubMed ID: 28546419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR.
    Loo TW; Clarke DM
    Biochem Pharmacol; 2017 Jul; 136():24-31. PubMed ID: 28366727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric coupling between the intracellular coupling helix 4 and regulatory sites of the first nucleotide-binding domain of CFTR.
    Dawson JE; Farber PJ; Forman-Kay JD
    PLoS One; 2013; 8(9):e74347. PubMed ID: 24058550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.
    Baatallah N; Elbahnsi A; Mornon JP; Chevalier B; Pranke I; Servel N; Zelli R; Décout JL; Edelman A; Sermet-Gaudelus I; Callebaut I; Hinzpeter A
    Cell Mol Life Sci; 2021 Dec; 78(23):7813-7829. PubMed ID: 34714360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
    Laselva O; Molinski S; Casavola V; Bear CE
    Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational changes relevant to channel activity and folding within the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator.
    Hudson RP; Chong PA; Protasevich II; Vernon R; Noy E; Bihler H; An JL; Kalid O; Sela-Culang I; Mense M; Senderowitz H; Brouillette CG; Forman-Kay JD
    J Biol Chem; 2012 Aug; 287(34):28480-94. PubMed ID: 22722932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based corrector combination restores ΔF508-CFTR folding and function.
    Okiyoneda T; Veit G; Dekkers JF; Bagdany M; Soya N; Xu H; Roldan A; Verkman AS; Kurth M; Simon A; Hegedus T; Beekman JM; Lukacs GL
    Nat Chem Biol; 2013 Jul; 9(7):444-54. PubMed ID: 23666117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
    Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
    Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein.
    He L; Kota P; Aleksandrov AA; Cui L; Jensen T; Dokholyan NV; Riordan JR
    FASEB J; 2013 Feb; 27(2):536-45. PubMed ID: 23104983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Measurement of Trafficking of the Cystic Fibrosis Transmembrane Conductance Regulator to the Cell Surface and Binding to a Chemical Chaperone.
    Zhang Z; Baksh MM; Finn MG; Heidary DK; Richards CI
    Biochemistry; 2017 Jan; 56(1):240-249. PubMed ID: 28001373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.
    Laselva O; Molinski S; Casavola V; Bear CE
    Mol Pharmacol; 2018 Jun; 93(6):612-618. PubMed ID: 29618585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.
    Lester A; Sandman M; Herring C; Girard C; Dixon B; Ramsdell H; Reber C; Poulos J; Mitchell A; Spinney A; Henager ME; Evans CN; Turlington M; Johnson QR
    Biochemistry; 2023 Aug; 62(16):2503-2515. PubMed ID: 37437308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site.
    Molinski SV; Shahani VM; Subramanian AS; MacKinnon SS; Woollard G; Laforet M; Laselva O; Morayniss LD; Bear CE; Windemuth A
    Proteins; 2018 Aug; 86(8):833-843. PubMed ID: 29569753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization.
    Chong PA; Farber PJ; Vernon RM; Hudson RP; Mittermaier AK; Forman-Kay JD
    J Biol Chem; 2015 Sep; 290(38):22862-78. PubMed ID: 26149808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
    Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
    Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.
    Farinha CM; King-Underwood J; Sousa M; Correia AR; Henriques BJ; Roxo-Rosa M; Da Paula AC; Williams J; Hirst S; Gomes CM; Amaral MD
    Chem Biol; 2013 Jul; 20(7):943-55. PubMed ID: 23890012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-Translational Folding of the First Transmembrane Domain of ABC-Transporter CFTR is Supported by Assembly with the First Cytosolic Domain.
    Kleizen B; van Willigen M; Mijnders M; Peters F; Grudniewska M; Hillenaar T; Thomas A; Kooijman L; Peters KW; Frizzell R; van der Sluijs P; Braakman I
    J Mol Biol; 2021 Jun; 433(13):166955. PubMed ID: 33771570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function.
    Rabeh WM; Bossard F; Xu H; Okiyoneda T; Bagdany M; Mulvihill CM; Du K; di Bernardo S; Liu Y; Konermann L; Roldan A; Lukacs GL
    Cell; 2012 Jan; 148(1-2):150-63. PubMed ID: 22265408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator.
    Bali V; Lazrak A; Guroji P; Fu L; Matalon S; Bebok Z
    FASEB J; 2016 Jan; 30(1):201-13. PubMed ID: 26336913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.